GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

11

EASL–AASLD PBC Consensus 2026: Journal of Hepatology | September 2026 | EASL–AASLD Delphi Consensus

ALP + bilirubin remain the core biochemical treatment targets Both ALP and total bilirubin at 12 months consistently predict clinically important outcomes in PBC, including decompensation, transplantation and...

12

HBsAg Negative Does Not Always Mean HBV Negative: Nature Reviews Gastroenterology & Hepatology | September 2026

What Does the Review Clarify? This major review provides a practical framework for understanding and investigating occult hepatitis B virus infection (OBI). OBI means replication-competent HBV DNA despite...

13

New PBC Consensus Makes Liver Stiffness Central to Follow-up: ÖGGH | September 2026

Introduction: PBC management is moving beyond simply starting UDCA and assessing response after one year. The new Austrian consensus emphasizes earlier biochemical assessment, more ambitious treatment targets, second-line...

14

MRCP Screening Reveals Unsuspected PSC in Nearly 1 in 10 Newly Diagnosed IBD Patients: CGH | September 2026

Introduction: PSC is strongly associated with IBD, but screening is usually prompted by abnormal liver biochemistry. The Copenhagen IBD inception cohort examined how often systematic MRCP at IBD...

15

MYR301: What Happens When Bulevirtide Is Stopped in Chronic Hepatitis D: Journal of Hepatology | September 2026 | Phase III MYR301 Trial

Introduction: Bulevirtide has transformed treatment of chronic hepatitis D (HDV), but the optimal treatment duration remains uncertain. Final MYR301 data address a crucial practical question: can treatment be...

16

FibroScan Liver Stiffness Strongly Predicts Outcomes in PSC: Gastroenterology | August 2026

Introduction: Risk stratification in primary sclerosing cholangitis (PSC) remains challenging because conventional biochemical markers do not reliably predict disease progression. The international FICUS cohort evaluated whether VCTE-based liver...

17

PBC in 2026: Is “Biochemical Response” No Longer Enough?: GastroAGI| August 2026

Topic: Evolving standards of care in primary biliary cholangitis (PBC), with increasing emphasis on ALP normalisation, liver stiffness, second-line PPAR agonists, pruritus, and fatigue. Key Takeaways The treatment...

18

Liver Biopsy Reveals Distinct Patterns of Checkpoint Inhibitor–Related Liver Injury: Hepatology Communications | August 2026

Introduction: Immune checkpoint inhibitors (ICIs) can cause immune-mediated liver injury, ranging from hepatocellular hepatitis to cholestatic or mixed patterns. Although liver biopsy may clarify the diagnosis and severity,...

19

Up to One in Four Patients With PBC May Already Have Cirrhosis at Diagnosis: Advance GastroHep | August 2026

Introduction: Primary biliary cholangitis (PBC) is a progressive cholestatic liver disease in which early diagnosis and treatment can prevent progression to cirrhosis. However, many patients remain asymptomatic and...

20

Pruritus in Primary Sclerosing Cholangitis: Hepatology | August 2026

Introduction: Pruritus is one of the most troublesome symptoms experienced by patients with primary sclerosing cholangitis (PSC), yet its natural history has been poorly understood. As disease-modifying therapies...

Previous
123456
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer